FINWIRES · TerminalLIVE
FINWIRES

UBS Downgrades MapLight Therapeutics to Neutral From Buy, Adjusts PT to $13 From $52

By

MapLight Therapeutics (MPLT) has an average rating of Buy and mean price target of $32.31, according to analysts polled by FactSet.

What else is happening in Research?